Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Metabolic Associated Fatty Liver Disease
NCT07185932Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifaximin in metabolic associated fatty liver disease (MAFLD), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Change in liver fat content measured by MRI proton density fat fraction at 24 weeks. Started Aug 2024; status: recruiting.
02
Drugs
rifaximin
03
Conditions
metabolic associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT07185932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185932.